跳至主要内容
临床试验/ACTRN12618000113257
ACTRN12618000113257已完成2 期

The effect of mepolizumab on patients with nasal polyp eosinophilia

Richard Harvey0 个研究点目标入组 20 人开始时间: 2018年1月29日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Adult patients with severe nasal polyp disease or eosinophilic chronic rhinosinusitis
  • Not currently receiving mepolizumab treatment
  • Patients who do not meet the PBS criteria for severe lower airway disease
  • Body weight: A minimum body weight >=40 kilograms (kg) at Visit 1
  • Gender: Male or female.
  • Informed consent: Capable of giving signed informed consent

排除标准

  • Subjects with known hypersensitivity to mepolizumab
  • Subjects with other conditions that could lead to elevated eosinophils such as Hypereosinophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic Esophagitis.
  • Subjects with known immunodeficiency
  • Subjects with cystic fibrosis

研究者

发起方
Richard Harvey

相似试验